MEDICA 2025: Shanghai Sun Bio Showcases Comprehensive Coagulation Solutions to the Global Market

From November 17 to 20, 2025, MEDICA was held in Düsseldorf. Shanghai Sun Bio took part in the event by presenting a comprehensive coagulation testing solution, demonstrating its expertise in thrombosis and hemostasis diagnostics to a global audience.

The presence of these “Made in China” solutions underscores a growing capacity to address worldwide healthcare needs.

As one of the world's most influential professional medical technology exhibitions, MEDICA attracts over 8,000 exhibitors from more than 70 countries and draws an audience of 50,000 industry professionals each year. At this year’s exhibition, Shanghai Sun Bio featured a full range of coagulation solutions—from compact semi-automated analyzers to high-throughput fully automated systems. The portfolio covers applications such as routine coagulation screening, fibrinolysis assessment, coagulation factor analysis, thrombophilia evaluation, and anticoagulant therapy monitoring, showcasing the company’s integrated technical strengths in the field of hemostasis and thrombosis.

Hemorrhagic and thrombotic diseases rank as the third leading cause of death globally, affecting hundreds of millions of people each year. There is a growing need for early screening, accurate diagnosis, and targeted treatment worldwide. Shanghai Sun Bio’s coagulation solutions are designed not only to meet the demands of mature markets for high throughput, multi-functionality, and automation but also to provide reliable and cost-effective diagnostic tools tailored to emerging.